Pushing the boundaries of imaging technology
We’re determined to push the boundaries of what imaging technology can achieve, to help develop next generation treatments with the potential to save or improve the lives of millions.
Pioneer of a new imaging diagnostic paradigm
We are transforming the imaging diagnostic world by developing the most accurate AI-powered digital biomarkers across multiple imaging modalities. Our focus is to achieve accurate early diagnosis to improve patient lives by helping radiologists and clinicians in their diagnostic workflow in oncology and metabolic diseases.
We deliver on a global scale
The combination of Median’s ground-breaking technology and world-class expertise perfectly positions us to revolutionize the field of medical imaging, transforming data generation, management, and access all around the world. Benefiting patients, health professionals, our partners and investors.
Median's latest news
We were happy to welcome a large audience during our webcast on Oct. 26th, 2022. The opportunity for Fredrik Brag, CEO and founder of Median, to share the company’s news and prospects and respond to the many questions from participants. The webcast recording is now available!
Latest press releases
Our Winter Corporate Newsletter
We are pleased to share with you our latest Corporate Newsletter, presenting our most recent announcements. Click below to read the Newsletter!
Webinars
Imaging for clinical trials
Advancing treatments of the future
Working with biopharma companies and leading medical centers around the world, the team at Median enable researchers to identify disease fingerprints from medical images. We’re helping paving the way for new personalized and innovative medicines, more accurate and predictable diagnoses and better treatments.
iBiopsy®
Enhancing imaging diagnostic accuracy
Our team of data scientists, AI engineers and clinicians is focused on developing the most accurate and cutting-edge AI-powered Software as a Medical Device (SaMD). iBiopsy® targets: lung cancer, liver cancer, and NASH to provide to patients an earlier and optimal diagnosis avoiding unnecessary invasive tests.
Investors
Delivering value
Our technology and expertise is creating a new world of possibilities for biopharmaceutical and healthcare professionals around the world. By successfully helping improve the lives of millions, we are also delivering value for our investors and partners.